Skip to main content

ASH Highlights

Meeting Highlights

ASH Highlights

Mosunetuzumab, a Bispecific Antibody, Induces Deep Remissions in Relapsed or Refractory Follicular Lymphoma

Meeting Highlights

ASH Highlights

Time-Limited Venetoclax Combinations Superior to Chemoimmunotherapy in Fit Patients with CLL

Meeting Highlights

ASH Highlights

Isatuximab plus RVd Regimen Achieves Highest Rates of No MRD in Patients with Multiple Myeloma

Meeting Highlights

ASH Highlights

Ivosidenib Added to First-Line Azacitidine Improves Outcomes in Older Patients with AML

Meeting Highlights

ASH Highlights

Polatuzumab Vedotin plus R-CHP Outperforms R-CHOP as First-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma

Meeting Highlights

ASH Highlights

A Paradigm Shift: CAR T-Cell Therapy Beats Standard of Care as Second-Line Treatment for Large B-Cell Lymphoma

Meeting Highlights

ASH Highlights

Immune Responses to COVID-19 Vaccines Low Among Patients with Hematologic Malignancies, but mRNA Vaccines Induce Strong Antibody Response in AML and MDS

Meeting Highlights

ASH Highlights, Leukemia, Novel Pharmaceuticals

Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia

Meeting Highlights

ASH Highlights, Myelofibrosis, Novel Pharmaceuticals

Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis

Meeting Highlights

ASH Highlights, CAR T-Cell Therapy, Lymphoma

ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma

1
2
3
4

Page 1 of 7
Results 1 - 10 of 70